
29th Hong Kong Medical Forum
03 May 2025 - 04 May 2025
Insights from latest CCS & ACS guidelines on lipid management
05 Jun 2025
byKanas Chan
The advent of new lipid-lowering agents, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, has led to guideline updates on management of chronic coronary syndrome (CCS) and acute coronary syndrome (ACS). In addition to potent LDL-cholesterol (LDL-C) reduction, alirocumab may mitigate atherosclerotic cardiovascular disease (ASCVD) risk by inducing plaque stabilization and exerting protective vascular effects.
Insights from latest CCS & ACS guidelines on lipid management
05 Jun 2025
T2D treatment goal shifts from glucose centricity to end-organ protection
28 May 2025
byKanas Chan
With the advent of disease-modifying agents such as tirzepatide, the current treatment goal for type 2 diabetes (T2D) extends beyond merely managing glycaemic levels to focusing on a broader approach that emphasizes end-organ protection.